Bristol Myers Lifts Sales Outlook To About $49.75 Billion-$50.25 Billion, Trims EPS Guidance On $0.60 Research Charge

Third-quarter revenue rose 7% to $13.1 billion, but adjusted EPS guidance fell to $6.35-$6.55 from $6.75-$7.00.

Share
Bristol Myers Lifts Sales Outlook To About $49.75 Billion-$50.25 Billion, Trims EPS Guidance On $0.60 Research Charge

Bristol Myers Squibb, the drugmaker behind Opdivo, Eliquis and Breyanzi, raised its 2026 revenue forecast to about $49.75 billion to $50.25 billion on Thursday. It also cut its adjusted per-share profit outlook to $6.35 to $6.55, as charges for licensed experimental drugs ate into earnings.

Sales up, profit guidance down

Third-quarter revenue rose 7% to $13.1 billion, the company reported. The Growth Portfolio, its newer and younger medicines, climbed 12% to $7.7 billion, and the Legacy Portfolio of older brands grew 1% to $5.4 billion.

The prior revenue range, set in July, was about $49.0 billion to $50.0 billion. Adjusted EPS guidance moved from $6.75-$7.00 to $6.35-$6.55. The new range includes a $0.60 per-share hit from acquired research charges and licensing income, against $0.02 assumed in July.

Third-quarter EPS was $1.05 on a standard accounting basis, down from $1.08, and $1.35 adjusted, down from $1.63. Acquired research charges and licensing income cost $0.58 per share, compared with $0.20 a year earlier. Those charges reached $1.6 billion, which the company tied mainly to recent license agreements and ongoing collaborations.

Eliquis carries the quarter

Eliquis, the blood thinner, rose 25% to $4.69 billion, and the company cited U.S. demand growth and market share gains. Opdivo slipped 6% to $2.37 billion, while its newer injectable form, Opdivo Qvantig, reached $334 million. Breyanzi rose 46% to $526 million and Camzyos rose 42% to $420 million.

Gross margin fell to 68.3% from 71.9% on a standard accounting basis, mainly from product mix and partly from a one-time contract termination charge. Revlimid fell 47% to $303 million and Pomalyst fell 81% to $130 million; the company's presentation notes that generic pomalidomide entered the U.S. in March.

CEO Christopher Boerner said the company delivered "another quarter of double-digit growth in our Growth Portfolio." Cash flow from operations was $4.2 billion in the quarter, and about $5 billion of share repurchase authorization remained as of September 30.

Pipeline dates ahead

The company plans to present Zenbexus data in relapsed multiple myeloma at the ASH meeting. The FDA's decision date for mezigdomide is May 13, 2027. Zenbexus won FDA approval in multiple myeloma on August 13.

Eliquis revenue growth guidance of 20% to 25% for 2026 was left unchanged.

Sources